Impact of body mass index on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: Insights from the ELDERLY ACS 2 trial: Nutrition, Metabolism and Cardiovascular Diseases

G. De Luca, M. Verdoia, S. Savonitto, L.A. Ferri, L. Piatti, D. Grosseto, N. Morici, I. Bossi, P. Sganzerla, G. Tortorella, M. Cacucci, M. Ferrario, E. Murena, G. Sibilio, S. Tondi, A. Toso, S. Bongioanni, A. Ravera, E. Corrada, M. MarianiL. Di Ascenzo, A.S. Petronio, C. Cavallini, G. Vitrella, R. Antonicelli, R. Rogacka, S. De Servi, the Elderly ACS 2 Investigators

Research output: Contribution to journalArticlepeer-review

Abstract

Background and aim: Elderly patients are at increased risk of hemorrhagic and thrombotic complications after an acute coronary syndrome (ACS). Frailty, comorbidities and low body weight have emerged as conditioning the prognostic impact of dual antiplatelet therapy (DAPT). The aim of the present study was to investigate the prognostic impact of body mass index (BMI) on clinical outcome among patients included in the Elderly-ACS 2 trial, a randomized, open-label, blinded endpoint study comparing low-dose (5 mg) prasugrel vs clopidogrel among elderly patients with ACS. Methods and results: Our population is represented by 1408 patients enrolled in the Elderly-ACS 2 trial. BMI was calculated at admission. The primary endpoint of this analysis was cardiovascular (CV) mortality. Secondary endpoints were all-cause death, recurrent MI, Bleeding Academic Research Consortium (BARC) type 2 or 3 bleeding, and re-hospitalization for cardiovascular reasons or stent thrombosis within 12 months after index admission. Patients were grouped according to median values of BMI (
Original languageEnglish
Pages (from-to)730-737
Number of pages8
JournalNutr. Metab. Cardiovasc. Dis.
Volume30
Issue number5
DOIs
Publication statusPublished - 2020

Keywords

  • Acute coronary syndrome
  • Body mass index
  • Elderly patients
  • acetylsalicylic acid
  • beta adrenergic receptor blocking agent
  • calcium antagonist
  • clopidogrel
  • dipeptidyl carboxypeptidase inhibitor
  • diuretic agent
  • hemoglobin
  • hydroxymethylglutaryl coenzyme A reductase inhibitor
  • nitrate
  • prasugrel
  • antithrombocytic agent
  • acute coronary syndrome
  • aged
  • all cause mortality
  • Article
  • body mass
  • cardiovascular mortality
  • cardiovascular risk
  • clinical outcome
  • clinical trial
  • controlled study
  • diabetes mellitus
  • estimated glomerular filtration rate
  • female
  • follow up
  • human
  • hypercholesterolemia
  • hypertension
  • loading drug dose
  • low drug dose
  • major clinical study
  • male
  • multicenter study
  • non ST segment elevation myocardial infarction
  • open study
  • outcome assessment
  • percutaneous coronary intervention
  • priority journal
  • randomized controlled trial
  • ST segment elevation myocardial infarction
  • adverse event
  • age
  • bleeding
  • cause of death
  • comorbidity
  • comparative study
  • diagnostic imaging
  • frail elderly
  • geriatric assessment
  • Italy
  • mortality
  • recurrent disease
  • risk assessment
  • risk factor
  • time factor
  • treatment outcome
  • very elderly
  • Acute Coronary Syndrome
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Body Mass Index
  • Cause of Death
  • Clopidogrel
  • Comorbidity
  • Female
  • Frail Elderly
  • Geriatric Assessment
  • Hemorrhage
  • Humans
  • Male
  • Non-ST Elevated Myocardial Infarction
  • Percutaneous Coronary Intervention
  • Platelet Aggregation Inhibitors
  • Prasugrel Hydrochloride
  • Recurrence
  • Risk Assessment
  • Risk Factors
  • ST Elevation Myocardial Infarction
  • Time Factors
  • Treatment Outcome

Fingerprint Dive into the research topics of 'Impact of body mass index on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: Insights from the ELDERLY ACS 2 trial: Nutrition, Metabolism and Cardiovascular Diseases'. Together they form a unique fingerprint.

Cite this